MétaCan
Menu
← Back to cohort

Examination of current status of cross-provincial border access for clinical trials for patients with cancer.

2023· article· en· W4379340293 on OpenAlexafffundabout
Claire Rim, Farwa Zaib, Kayla Touma, Mahmoud Hossami, Rhonda Abdel-Nabi, Dora Cavallo‐Medved, Olla Hilal, Zoe Driedger, Devinder Moudgil, Milica Paunic, Renée Nassar, Roaa Hirmiz, Lee McGrath, Caroline Hamm

Bibliographic record

VenueJournal of Clinical Oncology · 2023
Typearticle
Languageen
FieldMedicine
TopicEthics in Clinical Research
Canadian institutionsUniversity of WindsorWestern University
FundersNational Research Council CanadaTD Bank
KeywordsClinical trialMedicineReferralCancerCLARITYFamily medicineInternal medicine

Abstract

fetched live from OpenAlex

e18661 Background: Clinical trials are the gold standard for establishing new and reliable treatment options. Even though 80% of cancer patients state that they would be interested in entering a clinical trial, only 3% of adults with cancer participate in clinical trials due to several challenges. Through a Clinical Trials Navigator program, we have curated clinical trials for approximately 243 patients and 7% have entered onto clinical trials. However, none of the patients were referred to trials outside of their home province due to a lack of clarity on the cross-border referral process. The goal of this study is to analyze the availability of patients for participating in out-of-province clinical trials in the presence of a lack of policy for provincial border referrals. Methods: This study was conducted by doing clinical trial searches for cancer patients using several clinical trial search engines such as ClinicalTrials.Gov, CanadianCancerTrials.com, ClinicalTrialsOntario, 3CTN, and Q-CROC. We also used a search engine to compare the number of clinical studies available in various cities for the four most common types of cancer in Canada. After this, an analysis was performed on over 243 clinical trial searches. Results: Out of the 18 patients we observed, most of them had potential out-of-province trials, but none of them joined out-of-province trials because of the lack of information regarding the process. Also, province disparity in trial availability was found for the most common cancers in Canada. The numbers of trials available in Ontario and Quebec are much higher than the number of trials available in PEI and Newfoundland which is almost zero or zero. The home treatment center of most of the patients involved in this study was Windsor Regional Hospital, and all of them were from Ontario. Among the patients that were referred, most of them were referred to Princess Margaret Cancer Centre in Toronto. Again, none of the patients were referred to cancer centers out of Ontario. Conclusions: In conclusion, our findings reveal the province disparity in the number of clinical trials available. The lack of policies that inform Canadians on how to cross provincial boundaries to enter a clinical trial prevents them from receiving the most needed cutting-edge treatments, compromising potential patient outcomes. Therefore, we need more clarity on policies for the cross-border referral process.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.084
metaresearch head score (Gemma)0.310
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.916
Threshold uncertainty score0.622

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0840.310
Meta-epidemiology (narrow)0.0000.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0110.024
Science and technology studies0.0030.002
Scholarly communication0.0110.005
Open science0.0030.004
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0100.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.896
GPT teacher head0.806
Teacher spread0.090 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
DomainMethods
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes3
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicEthics in Clinical Research→French-language works237,207→